Scholar Rock Reports Q2 2026 Financial Results with $109.9M Net Loss

Scholar Rock Holding Corporation reported its financial results for the second quarter of 2026, revealing a net loss of $109.9 million, slightly down from a loss of $110.0 million in the same period last year. For the first half of 2026, the company recorded a net loss of $215.4 million, compared to a loss of $184.8 million in the first half of 2025. The company's total operating expenses for the second quarter were $108.9 million, a decrease of 2.9% from $112.1 million in the prior year, primarily driven by reduced research and development costs.

The company’s cash and cash equivalents increased significantly to $437.1 million as of June 30, 2026, up from $323.5 million at the end of 2025. This increase was attributed to proceeds from a new debt facility, sales under an at-the-market offering program, and the exercise of stock options. Scholar Rock's total assets rose to $523.5 million, compared to $404.3 million at the end of the previous fiscal year, while total liabilities increased to $269.8 million from $158.8 million, largely due to the new debt obligations.

In terms of operational developments, Scholar Rock continues to advance its lead product candidate, apitegromab, which is in development for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD). The company has initiated a Phase 2 trial for apitegromab in FSHD and is also conducting a long-term extension study for SMA. The company resubmitted its Biologics License Application (BLA) for apitegromab to the FDA in March 2026, which has been accepted with a Prescription Drug User Fee Act (PDUFA) action date set for September 30, 2026.

Scholar Rock's workforce has expanded, with an increase in employee-related expenses reflecting the hiring of additional personnel to support its commercialization efforts. The company reported a total of 121.6 million shares outstanding as of June 30, 2026, up from 108.5 million shares at the end of 2025. The company anticipates continued significant operating losses as it invests in the development of its product candidates and builds its infrastructure for potential commercialization.

Looking ahead, Scholar Rock expects to incur substantial expenses related to the ongoing development of apitegromab and other product candidates. The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations into the second half of 2027, but it will require additional capital to complete clinical development and commercialization efforts. The company remains focused on advancing its pipeline and is actively seeking partnerships for its additional programs.